Department of Public Health and Preventive Medicine, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu 222000, China
2.
Department of Pathology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, China
3.
Department of Clinical Medicine, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu 222000, China
4.
Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China
5.
Department of Epidemiology, Department of Social Medicine and Health Education, The Innovation Center for Social Risk Governance in Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China
Funds:
This work was supported by the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (grant number 17KJD330002)
the Science and Technology Development Fund of Nanjing Medical University (grant number 2017NJMUZD141) and the Science and Technology Development Fund of Kangda College of Nanjing Medical University (grant number
KD2016KYJJZD007, KD2016KYJJZD008). The funding agencies had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.
Identifying sensitive and specific biomarkers for early detection of cancer is immensely imperative for early diagnosis and treatment and better clinical outcome of cancer patients. This study aimed to construct a specific DNA methylation pattern of cancer suppressor genes and explore the feasibility of applying cell-free DNA based methylation as a biomarker for early diagnosis of esophageal squamous cell carcinoma (ESCC). We recruited early stage ESCC patients from Yangzhong County, China. The Illumina Infinium 450K Methylation BeadChip was used to onstruct a genome-wide DNA methylation profile. Then, differentiated genes were selected for the validation study using the Sequenom MassARRAY platform. The frequency of methylation was compared between cancer tissues, matched cell-free DNAs and normal controls. The specific methylation profiles were constructed, and the sensitivity and specificity were calculated. Seven CG sites in three genes CASZ1, CDH13 and ING2 were significantly hypermethylated in ESCC as compared with normal controls. A significant correlation was found between the methylation of DNA extracted from cancer tissues and matched plasma cell-free DNA, either for individual CG site or for cumulative methylation analysis. The sensitivity and specificity reached 100% at an appropriate cut-point using these specific methylation biomarkers. This study revealed that aberrant DNA methylation is a promising biomarker for molecular diagnosis of esophageal cancer. Hypermethylation of CASZ1, CDH13 and ING2 detected in plasma cell-free DNA can be applied as a potential noninvasive biomarker for diagnosis of esophageal cancer.
Xu Y, Wang Z, Pei B, et al. DNA methylation markers in esophageal cancer. Front Genet, 2024, 15: 1354195.
DOI:10.3389/fgene.2024.1354195
2.
Liu T, Li T, Ke S. Role of the CASZ1 transcription factor in tissue development and disease. Eur J Med Res, 2023, 28(1): 562.
DOI:10.1186/s40001-023-01548-y
3.
Jian H, Poetsch A. CASZ1: Current Implications in Cardiovascular Diseases and Cancers. Biomedicines, 2023, 11(7): 2079.
DOI:10.3390/biomedicines11072079
4.
Mao C, Huang C, Hu Z, et al. Transcription factor CASZ1 increases an oncogenic transcriptional process in tumorigenesis and progression of glioma cells. MedComm (2020), 2022, 3(4): e182.
DOI:10.1002/mco2.182
5.
Zhu H, Liu X. Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. Front Oncol, 2021, 11: 666340.
DOI:10.3389/fonc.2021.666340
6.
Salta S, Macedo-Silva C, Miranda-Gonçalves V, et al. A DNA methylation-based test for esophageal cancer detection. Biomark Res, 2020, 8(1): 68.
DOI:10.1186/s40364-020-00248-7
7.
Lin L, Cheng X, Yin D. Aberrant DNA Methylation in Esophageal Squamous Cell Carcinoma: Biological and Clinical Implications. Front Oncol, 2020, 10: 549850.
DOI:10.3389/fonc.2020.549850
8.
Wang M, Liang Y, Ibeagha-Awemu EM, et al. Genome-Wide DNA Methylation Analysis of Mammary Gland Tissues From Chinese Holstein Cows With Staphylococcus aureus Induced Mastitis. Front Genet, 2020, 11: 550515.
DOI:10.3389/fgene.2020.550515
9.
Wang X, Shi D, Zhao D, et al. Aberrant Methylation and Differential Expression of SLC2A1, TNS4, GAPDH, ATP8A2, and CASZ1 Are Associated with the Prognosis of Lung Adenocarcinoma. Biomed Res Int, 2020, 2020: 1807089.
DOI:10.1155/2020/1807089
10.
Blondel A, Benberghout A, Pedeux R, et al. Exploiting ING2 Epigenetic Modulation as a Therapeutic Opportunity for Non-Small Cell Lung Cancer. Cancers (Basel), 2019, 11(10): 1601.
DOI:10.3390/cancers11101601
11.
Singh A, Gupta S, Sachan M. Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives. Front Cell Dev Biol, 2019, 7: 182.
DOI:10.3389/fcell.2019.00182
12.
Kim B, Jung M, Moon KC. The Prognostic Significance of Protein Expression of CASZ1 in Clear Cell Renal Cell Carcinoma. Dis Markers, 2019, 2019: 1342161.
DOI:10.1155/2019/1342161